MRMarc Raynaud

Marc Raynaud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marc Raynaud has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Passions and Philosophies Behind Transplantation Medicine: A History of Great Minds

    by Marc Raynaud, Ivana Juric, Frank Martinez, Emilien Seizilles de Mazancourt, Emmanuel Martinod, Yvon Lebranchu, Alexandre Loupy

    The history of transplantation medicine is a journey of surgical and scientific breakthroughs. Yet it is also a reflection of human creativity, philosophy, and the search for meaning. This review retraces major milestones in transplantation history while highlighting the philosophical and artistic passions that shaped its pioneers. From early myths of hybrid beings to the first successful organ transplants, the field has challenged questions about life, identity, and the human condition. Many of transplantation’s pioneers approached medicine as both science and art. Thomas Starzl saw surgery as a deeply creative process, comparing his scalpel to an artist’s brush, shaping life with every movement. Christiaan Barnard loved literature, using novels to reflect on the moral and emotional complexities of his work. Jean Borel, while advancing immunosuppression, never abandoned his first love: painting. Overall, many figures in transplantation medicine engaged deeply with art and philosophy, questioning identity and the ethics of extending life. As innovations in xenotransplantation and artificial intelligence reshape the discipline, the philosophical and creative legacies of these great minds may continue to inspire progress and help us push the boundaries of what is possible.

  • Prédiction du risque et construction de scores pronostiques en transplantation rénale

    by Marc Raynaud

    Contexte : En dépit des progrès accomplis récemment dans le pronostic au long-terme après la greffe rénale, et bien que la fonction rénale soit un paramètre clé pour le suivi du transplanté rénal et la prise de décision, les connaissances sont encore limitées quant aux dynamiques des mesures répétées de la fonction rénale, leurs déterminants, et leur capacité à prédire la survie du greffon. Ces limites découlent principalement des données de registre dont la qualité est freinée par les échantillons cliniques de commodité, des cohortes de patients pauvres en information, et du manque d’approches statistiques appropriées et de validations externes. Basé sur une épidémiologie intégrative, notre but était de caractériser les trajectoires de fonction rénale après la greffe, d’identifier leurs déterminants, et de développer un système de prédiction dynamique de la survie du greffon au long cours. Méthodes : Nous avons construit des cohortes larges, prospectives et non-sélectionnées de patients français, européens, nord-américains and sud-américains. Les patients ont eu une évaluation prospective du débit de filtration glomérulaire estimé (DFGe) et de la protéinurie, et une évaluation des paramètres cliniques, biologiques, immunologiques et histologiques. Sept essais contrôlés randomisés (RCT) ont permis de constituer une cohorte de validation supplémentaire. Résultats : Au final, plus de 15 000 patients ont été inclus, et plus de 400 000 mesures de fonction rénale ont été évaluées À l’aide de modèles mixtes à classes latentes non-supervisés et de régressions multinomiales, nous avons identifié huit trajectoires de DFGe, leurs déterminants, et leurs associations avec les événements cliniques. Celles-ci étaient similaires à travers les pays, sur la base d’analyses indépendantes. Les trajectoires de DFGe ont également été validées dans plusieurs sous-populations. Des modèles joints ont révélé que le profil immunologique, les paramètres histologiques, et les mesures répétées de DFGe et protéinurie étaient des facteurs de risque indépendants de la survie du greffon. Le modèle dynamique final a démontré une calibration précise ainsi qu’une très haute discrimination dans la cohorte de dérivation (AUC=0.857), avec une amélioration croissante des AUCs pour chaque nouvelle mesure répétée. Les performances du modèle dynamique ont été confirmées dans toutes les cohortes de validation externes, ainsi que dans une large série de scénarios cliniques et de sous-populations. Conclusion : Ce travail répond à un besoin clinique pressant, dans le champ de la transplantation, de caractériser les trajectoires de fonction rénale, et adéquatement les utiliser dans un modèle de prédiction dynamique, conjointement aux déterminants cliniques, immunologiques, et histologiques de la survie du greffon. Les deux outils finaux de cette thèse -un système de prédiction de trajectoires de DFGe, et un système de prédiction dynamique de la survie du greffon- peuvent être facilement implémentés dans la pratique clinique quotidienne, et pourraient participer à améliorer la gestion du patient et la stratification du risque dans les essais cliniques.

  • Open Access

    Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system

    by Yannis Lombardi, Marc Raynaud, Martina Schatzl, Katharina A. Mayer, Matthias Diebold, Uptal D. Patel, Eva Schrezenmeier, Aylin Akifova, Klemens Budde, Alexandre Loupy, et al.


  • Competing and Noncompeting Risk Models for Predicting Kidney Allograft Failure

    by Agathe Truchot, Marc Raynaud, Ilkka Helanterä, Olivier Aubert, Nassim Kamar, Gillian Divard, Brad Astor, Christophe Legendre, Alexandre Hertig, Matthias Buchler, et al.

    Key Points: Prediction models are becoming increasingly relevant in precision medicine. These models should be highly performant and not negatively affected by competing risk events. We thus aimed to carefully assess the effect of competing risks in allograft failure prediction. Background: Prognostic models are becoming increasingly relevant in clinical trials as potential surrogate end points and for patient management as clinical decision support tools. However, the effect of competing risks on model performance remains poorly investigated. We aimed to carefully assess the performance of competing risk and noncompeting risk models in the context of kidney transplantation, where allograft failure and death with a functioning graft are two competing outcomes. Methods: We included 11,046 kidney transplant recipients enrolled in ten countries. We developed prediction models for long-term kidney graft failure prediction, without accounting ( i.e ., censoring) and accounting for the competing risk of death with a functioning graft, using Cox, Fine–Gray, and cause-specific Cox regression models. To this aim, we followed a detailed and transparent analytical framework for competing and noncompeting risk modeling and carefully assessed the models' development, stability, discrimination, calibration, overall fit, clinical utility, and generalizability in external validation cohorts and subpopulations. More than 15 metrics were used to provide an exhaustive assessment of model performance. Results: Among 11,046 recipients in the derivation and validation cohorts, 1497 (14%) lost their graft and 1003 (9%) died with a functioning graft after a median follow-up postrisk evaluation of 4.7 years (interquartile range, 2.7–7.0). The cumulative incidence of graft loss was similarly estimated by Kaplan–Meier and Aalen–Johansen methods (17% versus 16% in the derivation cohort). Cox and competing risk models showed similar and stable risk estimates for predicting long-term graft failure (average mean absolute prediction error of 0.0140, 0.0138, and 0.0135 for Cox, Fine–Gray, and cause-specific Cox models, respectively). Discrimination and overall fit were comparable in the validation cohorts, with concordance index ranging from 0.76 to 0.87. Across various subpopulations and clinical scenarios, the models performed well and similarly, although in some high-risk groups (such as donors older than 65 years), the findings suggest a trend toward moderately improved calibration when using a competing risk approach. Conclusions: Competing and noncompeting risk models performed similarly in predicting long-term kidney graft failure.


  • Open Access

    Identification of liver transplant biopsy phenotypes associated with distinct liver biological markers and allograft survival

    by Zeynep Demir, Marc Raynaud, Olivier Aubert, Dominique Debray, Mylène Sebagh, Jean-Paul Duong Van Huyen, Arnaud Del Bello, Nicolas Congy Jolivet, Valérie Paradis, François Durand, et al.


  • Top Cited Papers

    Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal

    by Marc Raynaud, Solaf Al-Awadhi, Kevin Louis, Huanxi Zhang, Xiaojun Su, Valentin Goutaudier, Jiali Wang, Zeynep Demir, Yongcheng Wei, Agathe Truchot, et al.

    Significance Statement: Why are there so few biomarkers accepted by health authorities and implemented in clinical practice, despite the high and growing number of biomaker studies in medical research ? In this meta-epidemiological study, including 804 studies that were critically appraised by expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient monitoring parameters. Most biomarker studies tended to be single-center, retrospective studies with a small number of patients and clinical events. Less than 5% of the studies performed an external validation. The authors also showed the poor transparency reporting and identified a data beautification phenomenon. These findings suggest that there is much wasted research effort in transplant biomarker medical research and highlight the need to produce more rigorous studies so that more biomarkers may be validated and successfully implemented in clinical practice. Background: Despite the increasing number of biomarker studies published in the transplant literature over the past 20 years, demonstrations of their clinical benefit and their implementation in routine clinical practice are lacking. We hypothesized that suboptimal design, data, methodology, and reporting might contribute to this phenomenon. Methods: We formed a consortium of experts in systematic reviews, nephrologists, methodologists, and epidemiologists. A systematic literature search was performed in PubMed, Embase, Scopus, Web of Science, and Cochrane Library between January 1, 2005, and November 12, 2022 (PROSPERO ID: CRD42020154747). All English language, original studies investigating the association between a biomarker and kidney allograft outcome were included. The final set of publications was assessed by expert reviewers. After data collection, two independent reviewers randomly evaluated the inconsistencies for 30% of the references for each reviewer. If more than 5% of inconsistencies were observed for one given reviewer, a re-evaluation was conducted for all the references of the reviewer. The biomarkers were categorized according to their type and the biological milieu from which they were measured. The study characteristics related to the design, methods, results, and their interpretation were assessed, as well as reproducible research practices and transparency indicators. Results: A total of 7372 publications were screened and 804 studies met the inclusion criteria. A total of 1143 biomarkers were assessed among the included studies from blood (n=821, 71.8%), intragraft (n=169, 14.8%), or urine (n=81, 7.1%) compartments. The number of studies significantly increased, with a median, yearly number of 31.5 studies (interquartile range [IQR], 23.8–35.5) between 2005 and 2012 and 57.5 (IQR, 53.3–59.8) between 2013 and 2022 (P < 0.001). A total of 655 studies (81.5%) were retrospective, while 595 (74.0%) used data from a single center. The median number of patients included was 232 (IQR, 96–629) with a median follow-up post-transplant of 4.8 years (IQR, 3.0–6.2). Only 4.7% of studies were externally validated. A total of 346 studies (43.0%) did not adjust their biomarker for key prognostic factors, while only 3.1% of studies adjusted the biomarker for standard-of-care patient monitoring factors. Data sharing, code sharing, and registration occurred in 8.8%, 1.1%, and 4.6% of studies, respectively. A total of 158 studies (20.0%) emphasized the clinical relevance of the biomarker, despite the reported nonsignificant association of the biomarker with the outcome measure. A total of 288 studies assessed rejection as an outcome. We showed that these rejection studies shared the same characteristics as other studies. Conclusions: Biomarker studies in kidney transplantation lack validation, rigorous design and methodology, accurate interpretation, and transparency. Higher standards are needed in biomarker research to prove the clinical utility and support clinical use.


  • New Equations for Estimating the GFR without Race

    by Marc Raynaud, Olivier Aubert, Alexandre Loupy

    To the Editor: Inker and colleagues (Nov. 4, 2021, issue)1 report the development of new equations to estimate the glomerular filtration rate (GFR) without the inclusion of race. Although the authors validated these equations in a series of previously published studies, the accuracy of the equations has not been confirmed in diverse subpopulations (e.g., in persons with hypertension or diabetes) or countries. Furthermore, we note that the numbers of Black persons with a measured GFR lower than 60 or 30 ml per minute per 1.73 m2 of body-surface area were 98 and 14, respectively, representing 2.4% and 0.3% of the . . .